The team investigated the discrepancies in remission rates for gastric mucosa-associated lymphoid tissue (MALT) lymphoma after eradication of Helicobacter pylori. They also determined the predictive factors of gastric lymphoma regression after the anti-H. pylori treatment.
The results of the trial have been reported in the March issue of Gut.
46 patients with localized gastric MALT lymphoma (Ann Arbor stages IE and IIE) were prospectively studied. All had gastric endoscopic ultrasonography and H. pyloristatus assessment.
After anti-H. pylori treatment, patients had histological reassessment every 4 months.
|Helicobacter pylori eradication is effective in causing MALT lymphoma regression.|
The researchers found that histological regression of the lymphoma was complete in 43% of patients.
Median follow-up time was 35 months.
No regression was noted in the 10 H. pylori-negative patients.
Among the 34 H. pylori-positive patients, the eradication rate was 100%; complete regression rate of the lymphoma increased from 56% to 79% when there was no nodal involvement at endoscopic ultrasonography.
There was a significant difference between the response of the lymphoma restricted to the mucosa and other more deep-seated lesions. However, using multivariate analysis, the researchers found that the only predictive factor of regression was the absence of nodal involvement.
Dr A Ruskoné-Fourmestraux, from Paris, France, concluded on behalf of the group, "In H. pylori-positive patients with localized gastric MALT lymphoma, without any lymph node involvement assessed by endoscopic ultrasonography, complete remission of lymphoma was reached in 79% of cases."